RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

James R. Bradford; Matthew Farren; Steve J. Powell; Sarah Runswick; Susie L. Weston; Helen Brown; Oona Delpuech; Mark Wappett; Neil R. Smith; T. Hedley Carr; Jonathan R. Dry; Neil J. Gibson; Simon T. Barry

doi:10.1371/journal.pone.0066003

Loading metrics

Open Access

Peer-reviewed

Research Article

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

James R. Bradford ,

* E-mail: James.Bradford@astrazeneca.com

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Matthew Farren,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Steve J. Powell,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Sarah Runswick,

Affiliation Personalised Healthcare and Biomarkers, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Susie L. Weston,

Affiliation Personalised Healthcare and Biomarkers, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Helen Brown,

Affiliation Personalised Healthcare and Biomarkers, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Oona Delpuech,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Mark Wappett,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Neil R. Smith,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
T. Hedley Carr,

Affiliation Personalised Healthcare and Biomarkers, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Jonathan R. Dry,

Affiliation Oncology, AstraZeneca Pharmaceuticals, Gatehouse Park, Massachusetts, United States of America
⨯
Neil J. Gibson,

Affiliation Personalised Healthcare and Biomarkers, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯
Simon T. Barry

Affiliation Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Cheshire, United Kingdom
⨯

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

James R. Bradford,
Matthew Farren,
Steve J. Powell,
Sarah Runswick,
Susie L. Weston,
Helen Brown,
Oona Delpuech,
Mark Wappett,
Neil R. Smith,
T. Hedley Carr

Published: June 19, 2013
https://doi.org/10.1371/journal.pone.0066003

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
RNA sequencing
Is the Subject Area "RNA sequencing" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Mammalian genomics
Is the Subject Area "Mammalian genomics" applicable to this article?

Thanks for your feedback.
Ribosomal RNA
Is the Subject Area "Ribosomal RNA" applicable to this article?

Thanks for your feedback.
Differentiated tumors
Is the Subject Area "Differentiated tumors" applicable to this article?

Thanks for your feedback.